Quanterix FY2024 EPS Forecast Decreased by Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Equities researchers at Leerink Partnrs decreased their FY2024 EPS estimates for Quanterix in a research report issued to clients and investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.94) for the year, down from their prior estimate of ($0.88). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.88) EPS.

Separately, TD Cowen increased their price objective on Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Trading Down 19.7 %

Quanterix stock opened at $9.42 on Thursday. The firm’s 50 day simple moving average is $11.99 and its 200 day simple moving average is $12.68. Quanterix has a 1-year low of $9.16 and a 1-year high of $29.70. The firm has a market capitalization of $362.90 million, a PE ratio of -8.97 and a beta of 1.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new stake in Quanterix during the third quarter worth about $60,000. Peapack Gladstone Financial Corp purchased a new position in shares of Quanterix during the 3rd quarter valued at about $131,000. SG Americas Securities LLC bought a new stake in Quanterix in the 3rd quarter worth approximately $139,000. Canada Pension Plan Investment Board purchased a new stake in Quanterix in the second quarter worth approximately $140,000. Finally, Hsbc Holdings PLC grew its position in Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock valued at $164,000 after acquiring an additional 3,279 shares during the last quarter. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.